Nextcure Stock Today
| NXTC Stock | USD 1.44 0.09 5.88% |
Performance4 of 100
| Odds Of DistressOver 55
|
NextCure is trading at 1.44 as of the 25th of April 2024, a -5.88 percent decrease since the beginning of the trading day. The stock's open price was 1.53. NextCure has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for NextCure are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of May 2019 | Category Healthcare | Classification Health Care |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. The company has 27.9 M outstanding shares of which 993.76 K shares are now shorted by private and institutional investors with about 1.78 trading days to cover. More on NextCure
Moving together with NextCure Stock
| 0.77 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.83 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.63 | CGC | Canopy Growth Corp Trending | PairCorr |
Moving against NextCure Stock
| 0.55 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
NextCure Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. NextCure's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding NextCure or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering NextCure report their recommendations after researching NextCure's financial statements, talking to executives and customers, or listening in on NextCure's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering NextCure. The NextCure consensus assessment is calculated by taking the average forecast from all of the analysts covering NextCure. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from NextCure's historical financial statements, NextCure is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of NextCure is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NextCure's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to NextCure's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NextCure's financial leverage. It provides some insight into what part of NextCure's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NextCure (NXTC) is traded on NASDAQ Exchange in USA. It is located in 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 and employs 82 people. NextCure is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NextCure's market, we take the total number of its shares issued and multiply it by NextCure's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NextCure conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.9 M outstanding shares of which 993.76 K shares are now shorted by private and institutional investors with about 1.78 trading days to cover.
NextCure currently holds about 185.49 M in cash with (52.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NextCure Probability Of Bankruptcy
Ownership AllocationNextCure maintains a total of 27.9 Million outstanding shares. Over half of NextCure's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in NextCure. Please watch out for any change in the institutional holdings of NextCure as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NextCure Ownership Details
NextCure Stock Price Odds Analysis
What are NextCure's target price odds to finish over the current price? Based on a normal probability distribution, the odds of NextCure jumping above the current price in 90 days from now is about 69.15%. The NextCure probability density function shows the probability of NextCure stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days NextCure has a beta of 0.4393. This indicates as returns on the market go up, NextCure average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding NextCure will be expected to be much smaller as well. Additionally, nextCure has an alpha of 0.5765, implying that it can generate a 0.58 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of NextCure to move above the current price in 90 days from now is about 69.15 (This NextCure probability density function shows the probability of NextCure Stock to fall within a particular range of prices over 90 days) .
NextCure Stock Institutional Holders
Institutional Holdings refers to the ownership stake in NextCure that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of NextCure's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NextCure's value.| Instituion | Recorded On | Shares | |
| Federated Hermes Inc | 2023-12-31 | 327.8 K | |
| Bml Capital Management Llc | 2023-12-31 | 306.5 K | |
| Renaissance Technologies Corp | 2023-12-31 | 293.3 K | |
| Geode Capital Management, Llc | 2023-12-31 | 174.7 K | |
| Macquarie Group Ltd | 2023-12-31 | 150 K | |
| Sio Capital Management, Llc | 2023-12-31 | 130 K | |
| Bridgeway Capital Management, Llc | 2023-12-31 | 94.6 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 85.9 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 80.8 K | |
| Orbimed Advisors, Llc | 2023-12-31 | 2.7 M | |
| Sofinnova Ventures | 2023-12-31 | 2.7 M |
NextCure Historical Income Statement
NextCure Income Statement is one of the three primary financial statements used for reporting NextCure's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of NextCure revenue and expense. NextCure Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, NextCure's Cost Of Revenue is projected to increase significantly based on the last few years of reporting. The current year's Non Operating Income Net Other is expected to grow to about 1.9 M, whereas Depreciation And Amortization is forecasted to decline to about 3.7 M. View More FundamentalsNextCure Stock Against Markets
Picking the right benchmark for NextCure stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in NextCure stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for NextCure is critical whether you are bullish or bearish towards NextCure at a given time. Please also check how NextCure's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in NextCure without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
NextCure Corporate Management
Elected by the shareholders, the NextCure's board of directors comprises two types of representatives: NextCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NextCure. The board's role is to monitor NextCure's management team and ensure that shareholders' interests are well served. NextCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NextCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA | Chief Officer | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Sebastien Maloveste | Senior Development | Profile | |
| Sourav Kundu | Senior Manufacturing | Profile | |
| Kevin Shaw | General Counsel | Profile | |
| Michael MSBA | CEO, CoFounder | Profile | |
| Lieping MD | CoFounder Board | Profile |
How to buy NextCure Stock?
Before investing in NextCure, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in NextCure. To buy NextCure stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of NextCure. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase NextCure stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located NextCure stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased NextCure stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as NextCure, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy NextCure Stock please use our How to Invest in NextCure guide.
Already Invested in NextCure?
The danger of trading NextCure is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of NextCure is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than NextCure. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile NextCure is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is NextCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Quarterly Revenue Growth (1.00) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.